Pomerantz Law Firm Investigates Potential Fraud Claims Against Argenx SE After FDA Alert
Pomerantz Law Firm Launches Investigation Into Argenx SE
The Pomerantz Law Firm has initiated an investigation concerning claims made by investors of argenx SE, a biopharmaceutical company traded on NASDAQ under the ticker symbol ARGX. The firm is examining whether argenx, along with some of its executives and directors, may have been involved in securities fraud or other unlawful business practices that could have affected the company's stock and investor returns.
Background of the Investigation
On June 30, 2025, the U.S. Food and Drug Administration (FDA) alerted the public about potential serious risks linked to argenx's product, Vyvgart Hytrulo. The FDA noted there were reports that suggested a
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.